heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer.
Company profile
Ticker
SCPX
Exchange
Website
CEO
Jeffrey Wolf
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HEAT BIOLOGICS, INC.
SEC CIK
Corporate docs
Subsidiaries
Heat Biologics, Inc • Heat Biologics I, Inc • Heat Biologics III, Inc. • Heat Biologics IV, Inc. • Heat Biologics GmbH. • Heat Biologics Australia Pty LTD • Zolovax, Inc. • Pelican Therapeutics, Inc. • Skunkworx Bio, Inc. • Scorpius BioManufacturing, Inc. ...
IRS number
262844103
SCPX stock data
Latest filings (excl ownership)
8-K
Scorpius Holdings Announces Receipt of Filing Delinquency Notification
22 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-A12B/A
Registration of securities on exchange (amended)
13 Mar 24
8-K
Scorpius Holdings, Inc. Announces Closing of Public Offering
13 Mar 24
8-K
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
11 Mar 24
424B5
Prospectus supplement for primary offering
11 Mar 24
FWP
Free writing prospectus
7 Mar 24
424B5
Prospectus supplement for primary offering
7 Mar 24
424B5
Prospectus supplement for primary offering
7 Mar 24
8-K
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023
7 Mar 24
Latest ownership filings
SC 13D/A
Wolf Jeffrey Alan
12 Dec 23
SC 13D/A
Wolf Jeffrey Alan
21 Aug 23
SC 13D/A
Wolf Jeffrey Alan
30 Dec 22
4
Jeffrey Alan Wolf
9 Dec 22
4
Edward B Smith III
9 Dec 22
4
JOHN K A PRENDERGAST
9 Dec 22
4
William L. Ostrander
9 Dec 22
4
JOHN J MONAHAN
9 Dec 22
4
JOHN K A PRENDERGAST
3 Jan 22
4
Edward B Smith III
3 Jan 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm | 5.36 mm |
Cash burn (monthly) | 158.05 k | 691.31 k | 3.74 mm | 4.84 mm | 2.82 mm | 3.19 mm |
Cash used (since last report) | 1.09 mm | 4.76 mm | 25.69 mm | 33.30 mm | 19.38 mm | 21.95 mm |
Cash remaining | 4.28 mm | 607.28 k | -20.33 mm | -27.94 mm | -14.02 mm | -16.59 mm |
Runway (months of cash) | 27.1 | 0.9 | -5.4 | -5.8 | -5.0 | -5.2 |
Institutional ownership, Q3 2023
10.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 7 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.11 bn |
Total shares | 3.82 mm |
Total puts | 2.60 k |
Total calls | 124.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.62 mm | $11.13 mm |
Vanguard | 1.10 mm | $578.64 mm |
BLK Blackrock | 409.12 k | $215.60 mm |
Geode Capital Management | 211.48 k | $111.48 mm |
STT State Street | 102.98 k | $54.27 mm |
Bridgeway Capital Management | 100.00 k | $52.70 mm |
Renaissance Technologies | 86.67 k | $46.00 k |
NTRS Northern Trust | 46.82 k | $24.67 mm |
MS Morgan Stanley | 41.46 k | $21.85 mm |
GS Goldman Sachs | 14.82 k | $7.81 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Dec 22 | Ostrander William L. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.02 | 490,196 | 500.00 k | 490,196 |
7 Dec 22 | John J Monahan | Stock Option Common Stock | Grant | Acquire A | No | No | 1.02 | 101,960 | 104.00 k | 101,960 |
7 Dec 22 | Prendergast John K A | Stock Option Common Stock | Grant | Acquire A | No | No | 1.02 | 203,921 | 208.00 k | 203,921 |
7 Dec 22 | Wolf Jeffrey Alan | Stock Option Common Stock | Grant | Acquire A | No | No | 1.02 | 2,843,137 | 2.90 mm | 2,843,137 |
7 Dec 22 | Edward B Smith III | Stock Option Common Stock | Grant | Acquire A | No | No | 1.02 | 101,960 | 104.00 k | 101,960 |
News
Scorpius Holdings Announces Receipt Of Filing Delinquency Notification
22 Apr 24
Scorpius Holdings Accepted As A Member Of The U.S. Government's BioMaP-Consortium
14 Mar 24
EXCLUSIVE: Healthcare Service Provider Scorpius Projects Over 375% Sequential Increase In Q4 Revenue
7 Mar 24
NightHawk Biosciences Completes Name Change To Scorpius Holdings; Trading To Commence Under "SCPX" Effective At The Market Open Today
6 Feb 24
Press releases
Scorpius Holdings, Inc. Announces Closing of Public Offering
12 Mar 24
Scorpius Holdings, Inc. Announces Pricing of Public Offering
8 Mar 24
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
7 Mar 24
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023
7 Mar 24